Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress

Cholangiocarcinoma (CCA) is the second most frequent primary liver cancer, following hepatocellular carcinoma (HCC). Progress in the molecular understanding of CCA has led to the development of several agents, including FGFR inhibitors, such as pemigatinib, whose approval has marked a new era in thi...

Full description

Bibliographic Details
Main Authors: Gennaro Gadaleta-Caldarola, Alessandro Rizzo, Vincenzo Dadduzio, Lucia Lombardi, Arianna Gadaleta-Caldarola, Stefania Infusino, Antonio Cusmai, Claudia Citrigno, Gennaro Palmiotti
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Current Oncology
Subjects:
cholangiocarcinoma
biliary tract cancer
pemigatinib
FGFR2
intrahepatic cholangiocarcinoma
liver cancer
Online Access:https://www.mdpi.com/1718-7729/29/10/626

Internet

https://www.mdpi.com/1718-7729/29/10/626

Similar Items